Lilly’s oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
Share Facebook Twitter LinkedIn Pinterest Email Check out the best highlights between the Baltimore Orioles and New York Yankees.
